<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Sollvander S</submitter><funding>Vetenskapsrådet</funding><funding>Åhlén-stiftelsen</funding><funding>Gun och Bertil Stohnes Stiftelse</funding><funding>Magnus Bergvalls Stiftelse</funding><funding>Demensförbundet</funding><funding>Uppsala Berzelii Center</funding><funding>Petrus och Augusta Hedlunds Stiftelse</funding><funding>Alzheimerfonden</funding><pagination>98</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5875007</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>15(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Currently, several amyloid beta (Aβ) antibodies, including the protofibril selective antibody BAN2401, are in clinical trials. The murine version of BAN2401, mAb158, has previously been shown to lower the levels of pathogenic Aβ and prevent Aβ deposition in animal models of Alzheimer's disease (AD). However, the cellular mechanisms of the antibody's action remain unknown. We have recently shown that astrocytes effectively engulf Aβ&lt;sub>42&lt;/sub> protofibrils, but store rather than degrade the ingested Aβ aggregates. In a co-culture set-up, the incomplete degradation of Aβ&lt;sub>42&lt;/sub> protofibrils by astrocytes results in increased neuronal cell death, due to the release of extracellular vesicles, containing N-truncated, neurotoxic Aβ.&lt;h4>Methods&lt;/h4>The aim of the presen</pubmed_abstract><journal>Journal of neuroinflammation</journal><pubmed_title>The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death.</pubmed_title><pmcid>PMC5875007</pmcid><funding_grant_id>#2012-2172</funding_grant_id><pubmed_authors>Erlandsson A</pubmed_authors><pubmed_authors>Lannfelt L</pubmed_authors><pubmed_authors>Sollvander S</pubmed_authors><pubmed_authors>Zysk M</pubmed_authors><pubmed_authors>Gallasch L</pubmed_authors><pubmed_authors>Nikitidou E</pubmed_authors><pubmed_authors>Sehlin D</pubmed_authors><pubmed_authors>Soderberg L</pubmed_authors></additional><is_claimable>false</is_claimable><name>The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death.</name><description>&lt;h4>Background&lt;/h4>Currently, several amyloid beta (Aβ) antibodies, including the protofibril selective antibody BAN2401, are in clinical trials. The murine version of BAN2401, mAb158, has previously been shown to lower the levels of pathogenic Aβ and prevent Aβ deposition in animal models of Alzheimer's disease (AD). However, the cellular mechanisms of the antibody's action remain unknown. We have recently shown that astrocytes effectively engulf Aβ&lt;sub>42&lt;/sub> protofibrils, but store rather than degrade the ingested Aβ aggregates. In a co-culture set-up, the incomplete degradation of Aβ&lt;sub>42&lt;/sub> protofibrils by astrocytes results in increased neuronal cell death, due to the release of extracellular vesicles, containing N-truncated, neurotoxic Aβ.&lt;h4>Methods&lt;/h4>The aim of the presen</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 Mar</publication><modification>2025-04-26T22:15:40.753Z</modification><creation>2019-03-26T23:23:24Z</creation></dates><accession>S-EPMC5875007</accession><cross_references><pubmed>29592816</pubmed><doi>10.1186/s12974-018-1134-4</doi></cross_references></HashMap>